Senseonics Holdings announced that its Eversense 365 implantable continuous glucose monitor has received CE Mark approval, allowing the device to be sold throughout the European Union. The approval, granted on January 29, 2026, gives the company immediate access to a market of more than 30 million people with diabetes and sets the stage for launches in Germany, Italy, Spain and Sweden in the coming months.
The CE Mark opens a new, multi‑year revenue stream for Senseonics. The EU market for blood glucose monitoring devices is estimated at $15.5 billion in 2025 and is projected to reach $30.2 billion by 2033, a CAGR of 8.8%. By adding 30 million patients to its addressable base, Senseonics positions itself to capture a larger share of this growing market, especially as the company’s one‑year implantable sensor offers a distinct alternative to the 10‑14‑day disposable patches that dominate the space.
Eversense 365’s one‑year sensor life is a key differentiator. The implantable design reduces the need for frequent replacements, lowers patient burden, and creates recurring demand driven by the implantation procedure. In the United States, the device has iCGM clearance and can integrate with automated insulin delivery systems, a capability that Senseonics plans to extend to European customers. The company’s strategy to take full commercialization control in Europe, moving away from its former partner Ascensia Diabetes Care, is expected to improve operating leverage and accelerate market penetration.
Financially, Senseonics has shown strong momentum in 2025. Q4 revenue rose 71% to $14.2 million, and full‑year revenue reached $35.2 million, a 57% increase from the prior year. Gross profit improved to $3.5 million in Q3 2025, a turnaround from the $4.1 million loss in the same quarter a year earlier. These results demonstrate the company’s ability to scale its implantable platform and generate healthy margins as it expands into new geographies.
President and CEO Tim Goodnow said the CE Mark approval is a “latest achievement in our long‑term growth strategy” and that 2026 will be an “exciting year” as the company drives commercial progress in both the U.S. and Europe. He highlighted the importance of integrating Eversense 365 with AID systems and the upcoming completion of the Gemini trial, which will further validate the device’s clinical value.
The announcement was well received by investors, reflecting confidence in Senseonics’ differentiated product and its expanding European footprint. While the company’s share price has declined 29% over the past six months, the approval signals a significant shift in its growth trajectory and market positioning.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.